FLNA

Filana Therapeutics is the renamed Cassava Sciences, and the filing makes the situation plain: 'We have no approved products,' the company is 'heavily dependent on the success of simufilam,' and — decisively — 'The FDA has placed a full clinical hold on our planned clinical studies.' After simufilam's original Alzheimer's thesis collapsed, management has pivoted the same molecule to TSC-related epilepsy, an indication in which it concedes it has 'a limited operating history' and 'no history of product approvals.' This is not a business with a temporary earnings problem; it is a research program whose sole asset is currently barred from advancing. The value here is a coin flip on the hold lifting and a novel, unproven mechanism eventually working — the kind of unknowable binary that fits 'avoid,' not 'buy the dip.'

The numbers confirm a company in wind-down, not scale-up. There is no real product revenue — the $41.1M 'revenue' is a stale FY2013 XBRL tag and every recent year shows revenue as '—,' so the 1.4x P/S is meaningless and should be ignored. FY2025 posted a -$91.0M net loss, a -232% operating margin, and a -122% ROE against a -$496M accumulated deficit. R&D was cut 61.8% to $26.6M, which flatters the -$32.3M operating cash burn (down 72%) but signals a program being throttled back rather than pushed forward. Total liabilities jumped 271.6% and current liabilities 273.1% off a low base — worth watching, though liabilities/equity is still a manageable 0.59x.